Share of TB treatment outcomes of MDR RR conventional regimen India 2007-2017

In 2017, the multiple drug resistant rifampicin resistant regimen saw a 48 percent success rate. The death rate and lost to follow up stood at 19 and 18 percent respectively, while the failure rate of the drug was two percent during the same time period.

在2017年，多药耐药性利福平耐药治疗方案的成功率达到了48%。死亡率及失访率分别达到了19%和18%，而在同一时间段内，该药物的失败率仅为2%。